Esperion Therapeutics
(NASDAQ) ESPR
Esperion Therapeutics Financials at a Glance
Market Cap
$670.27M
Revenue (TTM)
$403.13M
Net Income (TTM)
$22.68M
EPS (TTM)
$-0.21
P/E Ratio
-12.46
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$2.62
Volume
5,845,376.342
Open
$2.55
Price
$2.62
Volume
5,845,376.342
Open
$2.55
Previous Close
$2.61
Daily Range
$2.52 - $2.65
52-Week Range
$0.69 - $4.17
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$2.62
Volume
5,845,376.342
Open
$2.55
Previous Close
$2.61
Daily Range
$2.52 - $2.65
52-Week Range
$0.69 - $4.17
ESPR News
ESPR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Esperion Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
294
CEO
Sheldon L. Koenig, MBA
Website
www.esperion.comHeadquarters
Ann Arbor, MI 48108, US
ESPR Financials
Key Financial Metrics (TTM)
Gross Margin
64%
Operating Margin
15%
Net Income Margin
-6%
Return on Equity
0%
Return on Capital
37%
Return on Assets
-5%
Earnings Yield
-8.03%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$670.27M
Shares Outstanding
256.81M
Volume
5.85M
Short Interest
0.00%
Avg. Volume
5.00M
Financials (TTM)
Gross Profit
$273.91M
Operating Income
$60.27M
EBITDA
$60.27M
Operating Cash Flow
$13.09M
Capital Expenditure
$189.00K
Free Cash Flow
$12.90M
Cash & ST Invst.
$167.85M
Total Debt
$548.00M
Esperion Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$168.45M
+143.7%
Gross Profit
$140.59M
+223.3%
Gross Margin
83.46%
N/A
Market Cap
$670.27M
N/A
Market Cap/Employee
$2.20M
N/A
Employees
304
N/A
Net Income
$61.83M
+390.0%
EBITDA
$85.23M
+1850.5%
Quarterly Fundamentals
Net Cash
$380.15M
-148.7%
Accounts Receivable
$140.19M
+74.9%
Inventory
$105.12M
+11.3%
Long Term Debt
$458.30M
+90.7%
Short Term Debt
$89.70M
+56.5%
Return on Assets
-4.87%
N/A
Return on Invested Capital
36.51%
N/A
Free Cash Flow
$45.43M
+230.0%
Operating Cash Flow
$45.24M
+229.4%